ArticleTuberculosis (Edinburgh, Scotland)2009
Discovery and validation of new antitubercular compounds as potential drug leads and probes.
Article in Tuberculosis (Edinburgh, Scotland), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 36 citations in OpenAlex.
- Recent Advances of DprE1 Inhibitors againstACS omega · 2022Review
- A high-throughput whole cell screen to identify inhibitors of Mycobacterium tuberculosis.PloS one · 2019Article
- Article
- Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG.Chemistry & biology · 2015Article
- Compounds targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria.Nature chemical biology · 2015Article
- Article
- Identification of novel inhibitors of nonreplicating Mycobacterium tuberculosis using a carbon starvation model.ACS chemical biology · 2013Article
- A novel quinoline derivative that inhibits mycobacterial FtsZ.Tuberculosis (Edinburgh, Scotland) · 2013Article
- 6-Oxo and 6-thio purine analogs as antimycobacterial agents.Bioorganic & medicinal chemistry · 2013Article
- Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.ChemMedChem · 2013Article
- Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening.ACS chemical biology · 2012Article
- High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv.Tuberculosis (Edinburgh, Scotland) · 2012Article
- Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors.Bioorganic & medicinal chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Increasing multidrug resistance in Mycobacterium tuberculosis continues to diminish the number of effective drugs available for treatment of active tuberculosis. Although there are four new products (representing three new chemical classes) in clinical development, an active, robust pipeline of new chemical entities is critical to discovery of medicines to dramatically improve or shorten length of therapy via new mechanisms of action. In the absence of major pharmaceutical industry activity in tuberculosis drug development, the National Institute of Allergy and Infectious Diseases (NIAID) has supported the development of a high throughput screen for growth inhibitors of M. tuberculosis using a chemically diverse commercial library, a compound library available through the NIH Roadmap, Molecular Libraries Screening Center Network, and other compound sources. The rationale for these screens and suggested approaches for follow-up studies to identify compounds for advanced preclinical studies and as chemical probes of critical functions in M. tuberculosis, are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.